Phosphoglucomutase deficiency type 2

Phosphoglucomutase deficiency type 2 (PGM1 deficiency type 2) is a rare genetic disorder that affects the body's ability to metabolize carbohydrates properly. This condition is part of a group of disorders known as congenital disorders of glycosylation (CDG), specifically classified under Type I CDG, due to its impact on the early steps of the glycosylation pathway. Phosphoglucomutase 1 (PGM1) plays a critical role in the conversion of glucose-1-phosphate to glucose-6-phosphate, a key step in glycogen synthesis and gluconeogenesis. Mutations in the PGM1 gene lead to PGM1 deficiency type 2, resulting in a wide range of clinical manifestations, including growth retardation, muscle weakness, and liver dysfunction.

Symptoms and Clinical Features

The symptoms of PGM1 deficiency type 2 can vary widely among affected individuals. Common clinical features include:

• Hypoglycemia (low blood sugar)
• Muscle weakness
• Liver dysfunction
• Growth retardation
• Cardiomyopathy (heart muscle disease)
• Hormonal imbalances, including hypothyroidism
• Coagulopathy (bleeding disorder)

Due to the broad spectrum of symptoms, diagnosis can be challenging and often requires a combination of clinical evaluation and genetic testing.

Genetics

PGM1 deficiency type 2 is caused by mutations in the PGM1 gene, which is located on chromosome 1p31. This gene encodes the enzyme phosphoglucomutase 1, essential for the proper metabolism of glucose. The disorder is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the condition.

Diagnosis

Diagnosis of PGM1 deficiency type 2 involves a combination of clinical assessment, laboratory testing, and genetic analysis. Laboratory tests may reveal abnormalities such as hypoglycemia, elevated liver enzymes, and abnormal coagulation profiles. Genetic testing can confirm the diagnosis by identifying mutations in the PGM1 gene.

Treatment

There is no cure for PGM1 deficiency type 2, and treatment focuses on managing symptoms and preventing complications. Management strategies may include:

• Dietary modifications to manage hypoglycemia
• Hormone replacement therapy for hormonal imbalances
• Supplements to support liver function
• Physical therapy to improve muscle strength

Prognosis

The prognosis for individuals with PGM1 deficiency type 2 varies depending on the severity of symptoms and the effectiveness of management strategies. Early diagnosis and intervention can improve the quality of life and reduce the risk of severe complications.

This metabolic pathology related article is a stub. You can help WikiMD by expanding it.